

REGISTERED COMPANY NUMBER: 07790071 (England and Wales)  
REGISTERED CHARITY NUMBER: 1144342 (England and Wales)  
REGISTERED CHARITY NUMBER: SC043576 (Scotland)

**REPORT OF THE TRUSTEES AND**  
**UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**  
**FOR**  
**NARCOLEPSY UK**

TUESDAY



\*AB56MD4Y\*

A06

31/05/2022

#337

COMPANIES HOUSE

**NARCOLEPSY UK**

**CONTENTS OF THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 4
<b>Independent Examiner's Report</b>	5
<b>Statement of Financial Activities</b>	6
<b>Statement of Financial Position</b>	7
<b>Notes to the Financial Statements</b>	8 to 15

**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

The trustees present their report and accounts for the year ended 31st December 2021, which are also prepared to meet the requirements for a Director's report and accounts for companies house purpose.

The financial statements comply with the Charities Act 2011, the companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

**OBJECTIVES AND ACTIVITIES**

As set out in its Articles of Association, the objectives of Narcolepsy UK are to provide relief and aid to those suffering from narcolepsy. To that end, we support people with narcolepsy, their families, carers and others interested in improving their quality of life.

Our principal activities to achieve these objectives are:

- The promotion and organization of conferences relating to narcolepsy and its effects.
- The promotion and/or assistance in promoting and carrying out research, surveys and investigations into narcolepsy and its effects.
- Creating and funding strategies that make this work possible.
- Arranging and providing exhibitions, meetings, lectures, classes and training courses.
- Collecting and distributing information, primarily through the Narcolepsy UK media portfolio comprising website, Facebook, Twitter and social media generally.

Narcolepsy UK's achievements in relation to these objectives are summarised below under the heading Achievements and Performance.

Our vision is to help provide a world where narcolepsy is understood and people with narcolepsy have the support they need to ensure that their rights are upheld and that they have the same opportunities as others in society.

We will deliver our objectives by:

- Raising professional, political and public awareness and understanding of the needs of people with narcolepsy, their families and carers.
- Campaigning to influence the policies of legislators and funding bodies.
- Delivering relevant sustainable services that satisfy the needs of people with narcolepsy, their families and carers.
- Providing information and practical support to people with narcolepsy, their families and carers, either directly, in partnership with others or through facilitating and supporting the work of other organisations.
- Supporting research into the effects and management of narcolepsy.

We seek to work in partnership with those who share our vision and mission.

Our strategic aim is to achieve all this through a combination of fundraising, continuing dialogue with politicians, medical professionals, other patient groups across the European Union in particular and a variety of projects.

**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**ACHIEVEMENT AND PERFORMANCE**

**Core activities**

As planned, all core activity was undertaken under the umbrella of the Narcolepsy Charter focused on direct, interventional support across education, work, family and social care

Unfortunately, we were again unable to run our annual conference in September as social distancing requirements make the costs prohibitive due to the additional space need to utilise.

Our registered membership increased from 2348 to 3074 over the 12 month period.

The Narcolepsy Charter was supported by 1275 people.

Total Voluntary staff Hours - 2212

Total Voluntary Value of these hours - £32,667.00

**External Engagement**

Our continued engagement with pharmaceutical companies, in accordance with our policy statement, "Working with Pharmaceutical Companies", combined with several years of investment in our vision and the delivery of our major project, the Narcolepsy Charter has resulted in truly positive outcomes for the people with narcolepsy we represent.

Much of this work is unseen and has to remain that way as it is often carried out subject to formal confidentiality agreements with external parties and our inclusion is a mark of the professionalism with which Narcolepsy UK engage with the regulatory and industry worlds that we are so dependent on for our treatment.

We are only at this point because we possess the belief in what we do and have been able to translate this into relationships where finance, trust and integrity have been enablers for us to turn our knowledge into a collective, evidence-based charter that is now being referenced as part of industry new drug approvals.

It was our annual Narcolepsy UK conference in October 2017 when we launched the concept of a Narcolepsy UK Charter and we have never looked back. Thanks to all who completed it and also to those who believed in our vision and provided the financial support that enabled its creation. Adelphi Research, Lincoln Medical Limited, The National Lottery Community Fund and UCB Pharma.

National Institute for Health & Care Excellence, NICE recommended solriamfetol as an option for treating excessive daytime sleepiness in adults with narcolepsy if modafinil and either dexamfetamine or methylphenidate have not worked well enough or are not suitable.

This decision increases treatment options for people with narcolepsy, creating more opportunity for them to access effective treatment sooner. This is a key aim of Narcolepsy UK's Charter as access to effective treatment can dramatically improve multiple aspects of people's lives including their education, working, family and social life

We welcome NICE's decision and the committee's recognition of the need for pragmatism when faced with limited evidence with which to compare the cost-effectiveness of treatments for rare diseases such as narcolepsy.

However, the guidance still leaves people with narcolepsy to be treated with drugs that have not been assessed in randomised clinical trials (dexamfetamine) or in RCTs in people with narcolepsy (methylphenidate) before newer drugs that have specifically been developed and tested for this disabling condition. Neither is there real-world evidence concerning long term safety issues that may be associated with dexamfetamine or methylphenidate. We believe that this scenario should be reviewed to guide future appraisals for narcolepsy treatments and for other medical conditions that might face similar issues.

**Anticipated Next Steps**

Here are the timelines that we anticipate will run from now until the end of the mandated 90 day implementation period for adopting the NICE determination, which starts from 18/11/21. We add the caveat that these are based on our perspective and the way each commissioning area adopts the guidance may vary.

18/11/21 Final Appraisal Determination (FAD) will be published on the NICE website for public consultation

**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

02/12/21 . End of the public consultation period

05/01/22 Technology Appraisal Guidance (TAG) will be published on the NICE website - this is the final recommendation document from NICE

17/01/22 The NHS in Wales must provide funding and resources for NICE recommended treatments within 60 days of the first publication of the FAD. This implementation date will be 17th January 2022

16/02/22 The NHS in England must comply with the recommendations of NICE within 90 days following the publication of the Technology Appraisal Guidance (TAG). This implementation date will be 16th February 2022

**FINANCIAL REVIEW**

Financial Review and Results for the year:

In the year 2021 the organisation received grants and other income totalling £63,431 and had outgoings totalling £59,714. The surplus of £3,717 has been added to the reserves brought forward. The income and outgoings include all those relating to the running of the general advise service and those relating to specific projects. On the balance sheet the organisation holds £20,030 of unrestricted funds and £39,875 in restricted funds. It is the charity's policy where possible to maintain unrestricted reserves of at least 6 months' general running costs.

**Reserves policy**

Free reserves available for use by Narcolepsy UK are deemed to be those that are readily realisable, less funds whose uses are restricted or designated for particular purposes.

Narcolepsy UK introduced a policy relating to reserves. Unrestricted assets should be apportioned between an "operating reserve" held to cover six months' cash flow, and then a "capital reserve" to be held against future liability to expenditure.

The operational reserve should hold liquid assets (cash or near cash), the total of which should equate to at least six months' cash flow. However, this is not always possible requiring careful management of available funds during critical periods and sourcing new income streams. In the medium term the Trustees believe that all activities should be self-funding and any additional income should be placed in a free reserve whose policy should be to maximise income.

**Risk management**

With income, the major risk is of a decline in Trust-related income particularly due to economic or other factors leading to both declining legacy values and reduced donations. This is something which has been and will continue to be addressed on a daily basis. Alongside this more project related funding will be sourced.

**Going concern**

The Trustees have reviewed the circumstances of Narcolepsy UK and consider that adequate resources continue to be available to fund the activities of the charity in the medium term. The trustees are of the view the charity is a going concern.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

07790071 (England and Wales)

**Registered Charity number**

1144342

**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**Registered office**

Yew Tree House  
The Shrubbery  
Church Street  
St Neots  
Cambridgeshire  
PE19 2BU

**Trustees**

M M O'Neil	Chair
E J Coates	Trustee
T J Kavanagh	Trustee
A J Molloy	Trustee
E H Nicholls	Trustee
H Strongman	Trustee


**Company Secretary**

Mrs N S Rule

**Independent Examiner**

Bradshaw Johnson  
Chartered Accountants  
Croft Chambers  
11 Bancroft  
Hitchin  
Hertfordshire  
SG5 1JQ

Approved by order of the board of trustees on 2nd March 22 and signed on its behalf by:



.....  
M M O'Neil - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF**  
**NARCOLEPSY UK**

**Independent examiner's report to the trustees of Narcolepsy UK ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2021.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').


Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Neil C Harding FCA  
Institute of Chartered Accountants in England and Wales  
Bradshaw Johnson  
Chartered Accountants  
Croft Chambers  
11 Bancroft  
Hitchin  
Hertfordshire  
SG5 1JQ

Date: ..... 27-5-22 .....

**NARCOLEPSY UK**

**STATEMENT OF FINANCIAL ACTIVITIES**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

	Notes	Unrestricted fund £	Restricted fund £	31.12.21 Total funds £	31.12.20 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies	3	38,947	7,500	46,447	80,818
Other trading activities	4	16,982	-	16,982	1,368
Investment income	5	<u>2</u>	<u>-</u>	<u>2</u>	<u>23</u>
<b>Total</b>		55,931	7,500	63,431	82,209
 <b>EXPENDITURE ON</b>					
Raising funds		852	-	852	2,580
<b>Charitable activities</b>	6				
Narcolepsy UK		<u>58,862</u>	<u>-</u>	<u>58,862</u>	<u>58,480</u>
<b>Total</b>		<u>59,714</u>	<u>-</u>	<u>59,714</u>	<u>61,060</u>
<b>NET INCOME/(EXPENDITURE)</b>		(3,783)	7,500	3,717	21,149
 <b>RECONCILIATION OF FUNDS</b>					
<b>Total funds brought forward</b>		<u>23,813</u>	<u>32,375</u>	<u>56,188</u>	<u>35,039</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u>20,030</u>	<u>39,875</u>	<u>59,905</u>	<u>56,188</u>

The notes form part of these financial statements



**NARCOLEPSY UK (REGISTERED NUMBER: 07790071)**

**STATEMENT OF FINANCIAL POSITION**  
**31 DECEMBER 2021**

	Notes	Unrestricted fund £	Restricted fund £	31.12.21 Total funds £	31.12.20 Total funds £
<b>FIXED ASSETS</b>					
Tangible assets	11	1,489	-	1,489	421
<b>CURRENT ASSETS</b>					
Debtors	12	3,012	-	3,012	7,620
Cash at bank		<u>17,116</u>	<u>39,875</u>	<u>56,991</u>	<u>50,927</u>
		20,128	39,875	60,003	58,547
<b>CREDITORS</b>					
Amounts falling due within one year	13	(1,587)	-	(1,587)	(2,780)
<b>NET CURRENT ASSETS</b>		<u>18,541</u>	<u>39,875</u>	<u>58,416</u>	<u>55,767</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>20,030</u>	<u>39,875</u>	<u>59,905</u>	<u>56,188</u>
<b>NET ASSETS</b>		<u>20,030</u>	<u>39,875</u>	<u>59,905</u>	<u>56,188</u>
<b>FUNDS</b>	14				
Unrestricted funds				20,030	23,813
Restricted funds				<u>39,875</u>	<u>32,375</u>
<b>TOTAL FUNDS</b>				<u>59,905</u>	<u>56,188</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2021.


The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 2nd March 2022 and were signed on its behalf by:

  
.....  
M M O'Neill - Trustee

The notes form part of these financial statements

## NARCOLEPSY UK

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

#### 1. STATEMENT OF COMPLIANCE

Narcolepsy UK is a charitable company incorporated in England. The registered office is:

Yew Tree House  
The Shrubbery  
Church Street  
St Neots  
Cambridgeshire  
PE19 2BU

The charitable company's financial statements have been prepared in compliance with Charities SORP (FRS 102) as it applies to the financial statements for the year ended 31 December 2021.

#### 2. ACCOUNTING POLICIES

##### **Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Narcolepsy UK meets the definition of a public benefit entity under FRS 102.

The financial statements are presented in sterling (£).

##### **Income**

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy in whole or in part, is only considered probably when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution.

##### **Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

##### **Expenditure and irrecoverable vat**

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

- Costs of raising funds comprise the costs of their associated support costs.
- Expenditure on charitable activities includes the costs of conferences and fundraising and their associated support costs.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

**NARCOLEPSY UK**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**2. ACCOUNTING POLICIES - continued**

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Pensions**

During the year, the charitable company operated a pension scheme with B&CE Holdings Ltd. Contributions payable for the year are charged in the profit and loss account.

**Legal status of the charitable company**

In the event of the charitable company being wound up, each Trustee (being a member of the charity) has undertaken to contribute to the assets of the charitable company such amounts as required not exceeding £1. This guarantee extends until one year after a Trustee ceases to be a member. The Trustees control the charitable company.

**Debtors and prepayments**

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**Cash at bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**Creditors**

Creditors are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

**Financial instruments**

The charitable company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**NARCOLEPSY UK**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**3. DONATIONS AND LEGACIES**

	31.12.21	31.12.20
	£	£
Donations	38,947	26,443
Grants	7,500	51,375
Sponsorships	<u>-</u>	<u>3,000</u>
	<u>46,447</u>	<u>80,818</u>

Grants received, included in the above, are as follows:

	31.12.21	31.12.20
	£	£
Other grants	<u>7,500</u>	<u>51,375</u>

**4. OTHER TRADING ACTIVITIES**

	31.12.21	31.12.20
	£	£
Fundraising events	<u>16,982</u>	<u>1,368</u>

**5. INVESTMENT INCOME**

	31.12.21	31.12.20
	£	£
Bank interest	<u>2</u>	<u>23</u>

**6. CHARITABLE ACTIVITIES COSTS**

	Unrestricted funds £	Restricted funds £	Total 2021 £	Total 2020 £
Advocacy Services	-	-	-	-
Staff cost	43,524	1,061	44,585	47,813
Bookkeeping	1,500	-	1,500	1,500
Independent Examiner's fees	1,204	-	1,204	260
Local and regional support	-	-	-	180
Office and miscellaneous	3,128	-	3,128	461
Telephone and fax	2,198	-	2,198	1,516
Training	-	-	-	-
Travel costs	394	-	394	868
Website development and maintenance	1,540	-	1,540	1,736
Insurance	1,707	-	1,707	1,825
Subscriptions	1,753	-	1,753	1,921
Marketing	-	-	-	-
Bank charges	394	-	394	388
Other apportionment	-	-	-	-
	<u>57,342</u>	<u>1,061</u>	<u>58,403</u>	<u>58,468</u>

**NARCOLEPSY UK**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**7. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	31.12.21	31.12.20
	£	£
Depreciation - owned assets	<u>459</u>	<u>12</u>

**8. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 December 2021 nor for the year ended 31 December 2020.

**Trustees' expenses**

There were no trustees' expenses paid for the year ended 31 December 2021 nor for the year ended 31 December 2020.

Trustees' expenses for the year were mainly for trustees' meetings.

**9. STAFF COST**

The average monthly number of employees during the year was as follows:

	31.12.21	31.12.20
Average monthly number of employees	3	5

No employees received emoluments in excess of £60,000.

**Employment costs**

Wages and salaries	44,585	46,331
Pension costs	<u>-</u>	<u>1,482</u>
	<u>44,585</u>	<u>47,813</u>

**10. 2020 COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted fund £	Restricted fund £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	69,443	11,375	80,818
Other trading activities	1,368	-	1,368
Investment income	<u>23</u>	<u>-</u>	<u>23</u>
<b>Total</b>	70,834	11,375	82,209
<b>EXPENDITURE ON</b>			
Raising funds	2,580	-	2,580
<b>Charitable activities</b>			
Narcolepsy UK	58,480	-	58,480
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Total</b>	61,060	-	61,060

**NARCOLEPSY UK**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

<b>10. 2020 COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued</b>	<b>Unrestricted fund £</b>	<b>Restricted fund £</b>	<b>Total funds £</b>
<b>NET INCOME</b>	9,774	11,375	21,149
 <b>RECONCILIATION OF FUNDS</b>			
<b>Total funds brought forward</b>	14,039	21,000	35,039
 <b>TOTAL FUNDS CARRIED FORWARD</b>	<u>23,813</u>	<u>32,375</u>	<u>56,188</u>
 <b>11. TANGIBLE FIXED ASSETS</b>			
			<b>Computer equipment £</b>
<b>COST</b>			
At 1 January 2021			433
Additions			<u>1,527</u>
At 31 December 2021			<u>1,960</u>
 <b>DEPRECIATION</b>			
At 1 January 2021			12
Charge for year			<u>459</u>
At 31 December 2021			<u>471</u>
 <b>NET BOOK VALUE</b>			
At 31 December 2021			<u>1,489</u>
At 31 December 2020			<u>421</u>
 <b>12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR</b>			
	<b>31.12.21 £</b>	<b>31.12.20 £</b>	
Other debtors	1,322	5,677	
Prepayments	<u>1,690</u>	<u>1,943</u>	
	<u>3,012</u>	<u>7,620</u>	

**NARCOLEPSY UK**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.21 £	31.12.20 £
Accruals	1,525	2,719
Deferred income - Sponsorship income	-	
Others	<u>62</u>	<u>62</u>
	<u><u>1,587</u></u>	<u><u>10,278</u></u>

**14. MOVEMENT IN FUNDS**

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
<b>Unrestricted funds</b>			
General fund	23,813	(3,783)	20,030
<b>Restricted funds</b>			
Local and Regional Support	<u>32,375</u>	<u>7,500</u>	<u>39,875</u>
<b>TOTAL FUNDS</b>	<u><u>56,188</u></u>	<u><u>3,717</u></u>	<u><u>59,905</u></u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	55,931	(59,714)	(3,783)
<b>Restricted funds</b>			
Local and Regional Support	<u>7,500</u>	<u>-</u>	<u>7,500</u>
<b>TOTAL FUNDS</b>	<u><u>63,431</u></u>	<u><u>(59,714)</u></u>	<u><u>3,717</u></u>

**Comparatives for movement in funds**

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
<b>Unrestricted funds</b>			
General fund	14,039	9,774	23,813
<b>Restricted funds</b>			
Local and Regional Support	<u>21,000</u>	<u>11,375</u>	<u>32,375</u>
<b>TOTAL FUNDS</b>	<u><u>35,039</u></u>	<u><u>21,149</u></u>	<u><u>56,188</u></u>

**NARCOLEPSY UK**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**14. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	70,834	(61,060)	9,774
<b>Restricted funds</b>			
Local and Regional Support	11,375	-	11,375
	<u>82,209</u>	<u>(61,060)</u>	<u>21,149</u>
<b>TOTAL FUNDS</b>			

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.20 £	Net movement in funds £	At 31.12.21 £
<b>Unrestricted funds</b>			
General fund	14,039	5,991	20,030
<b>Restricted funds</b>			
Local and Regional Support	21,000	18,875	39,875
	<u>35,039</u>	<u>24,866</u>	<u>59,905</u>
<b>TOTAL FUNDS</b>			

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	126,765	(120,774)	5,991
<b>Restricted funds</b>			
Local and Regional Support	18,875	-	18,875
	<u>145,640</u>	<u>(120,774)</u>	<u>24,866</u>
<b>TOTAL FUNDS</b>			



**NARCOLEPSY UK**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**15. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 December 2021.

**16. NAMES AND PURPOSE OF FUNDS**

**Local and Regional Support**

These funds have been donated specifically to allow the charity to provide support and information services within a particular region, both through enabling the creation and development of local volunteer/supporter sub groups which are better able to focus on local needs and through the provision of a local and regional support infrastructure to ensure that such groups operate efficiently and effectively in a co-ordinated manner to the highest standards.

**General**

This fund reflects the accumulated surplus arising from the general activity of the charity after allocating income and expenditure to other funds where appropriate and consistent with policy of the charity.